Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Innate Pharma (IPHYF) EBT Margin (2019 - 2025)

Historic EBT Margin for Innate Pharma (IPHYF) over the last 7 years, with Q2 2025 value amounting to 807.14%.

  • Innate Pharma's EBT Margin fell 5147300.0% to 807.14% in Q2 2025 from the same period last year, while for Jun 2025 it was 130.79%, marking a year-over-year decrease of 1306100.0%. This contributed to the annual value of 245.87% for FY2024, which is 2335900.0% down from last year.
  • Per Innate Pharma's latest filing, its EBT Margin stood at 807.14% for Q2 2025, which was down 5147300.0% from 360.45% recorded in Q4 2024.
  • Innate Pharma's EBT Margin's 5-year high stood at 1.61% during Q2 2023, with a 5-year trough of 807.14% in Q2 2025.
  • Its 5-year average for EBT Margin is 258.86%, with a median of 292.4% in 2024.
  • As far as peak fluctuations go, Innate Pharma's EBT Margin soared by 3423600bps in 2022, and later crashed by -5147300bps in 2025.
  • Over the past 5 years, Innate Pharma's EBT Margin (Quarter) stood at 342.48% in 2021, then surged by 100bps to 0.12% in 2022, then crashed by -9351bps to 11.05% in 2023, then crashed by -3162bps to 360.45% in 2024, then plummeted by -124bps to 807.14% in 2025.
  • Its EBT Margin was 807.14% in Q2 2025, compared to 360.45% in Q4 2024 and 292.4% in Q2 2024.